Enable AccessibilityEnable Accessibility

Senior Appointments At Shire

June 1, 2012


David Colpman to head global Business Development team; Ann Judge, global head of Human Resources joins Leadership Team

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces promotion of two senior leaders within Shire.

David Colpman, Senior Vice President, will assume responsibility for leading Shire’s global Business Development team, effective June 1st.  After nearly eight years of successful leadership at Shire, Barbara Deptula, Executive Vice President and Chief Corporate Development Officer, has announced her retirement from Shire effective June 29th.

David has over 12 years of experience with Shire.  During this time, David has been the lead on many of Shire’s significant deals. Before joining Shire he worked at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals in a variety of business development and commercial roles.  David is a member of the Royal Pharmaceutical Society and began his industry career at ICI (now AstraZeneca) in formulation and manufacturing. David will report to Shire Chief Executive, Angus Russell.

Ann Judge, Senior Vice President of Shire’s global Human Resources (HR) team has joined the Shire Leadership Team. Ann has over 20 years of global HR experience in the pharmaceutical, chemical, and oil and gas industries, having begun her career with Dow Chemical.  She lived and worked in Germany in the late1990s and relocated to Switzerland in early 2000s, where she also supported the commercial Asia Pacific Region.  Ann joined to lead the global HR team at Shire in late 2010, after six years with Wyeth Pharmaceuticals.

For further information please contact:



Jessica Mann (Corporate)

[email protected]

+44 1256 894 280


Notes to editors


Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: .


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.